A5052210949- Epilepsy research and treatment
- Drug Transport and Resistance Mechanisms
- Pharmacological Effects and Toxicity Studies
- Neuroscience and Neuropharmacology Research
- Erythropoietin and Anemia Treatment
- Hemoglobinopathies and Related Disorders
- Cancer, Hypoxia, and Metabolism
- Cannabis and Cannabinoid Research
- Complement system in diseases
- Pharmacogenetics and Drug Metabolism
- Mitochondrial Function and Pathology
- Trace Elements in Health
- Ion channel regulation and function
- Glioma Diagnosis and Treatment
- Blood groups and transfusion
- Neuroinflammation and Neurodegeneration Mechanisms
- Adipose Tissue and Metabolism
- Iron Metabolism and Disorders
- Tuberous Sclerosis Complex Research
- Biosimilars and Bioanalytical Methods
- Alzheimer's disease research and treatments
- Sirtuins and Resveratrol in Medicine
- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Adenosine and Purinergic Signaling
University of Buenos Aires
2014-2025
Instituto de Química y Fisicoquímica Biológicas
2014-2025
Hospital de Clínicas "José de San Martín"
2020-2023
Universidade Federal de São Paulo
2021
Universidade Federal de Mato Grosso do Sul
2021
Fundación para la Investigación, Docencia y Prevención del Cáncer
2014
Universidad de Montevideo
2013
Consejo Nacional de Investigaciones Científicas y Técnicas
2010
National Cancer Institute
2008
National Institutes of Health
2008
Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement-mediated hemolysis associated with paroxysmal nocturnal hemoglobinuria (PNH). The molecular basis for the poor response to eculizumab in small population of Japanese patients unclear.We assessed sequences gene encoding PNH who had either good or eculizumab. We also evaluated functional properties as it was encoded these patients.Of 345 received eculizumab, 11 response. All single...
Sleep apnea (SA) can be effectively managed in humans but it is recognized that when left untreated, SA causes long-lasting changes neuronal circuitry the brain. Recent neuroimaging studies gave suggested these are also present even patients successfully treated for acute effects of SA. The cellular mechanisms account not certain animal models intermittent hypoxia (IH) during sleep have shown death and impairment learning memory. Reactive gliosis has a drastic effect on survival this study...
Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx the Latin American and Caribbean (LAC) region remains scarce, with limited information some populations. Thus, extrapolations are complicated, especially mixed In this paper, we reviewed analyzed pharmacogenomic knowledge among LAC scientific clinical community examined barriers to application. We performed a search for publications trials worldwide evaluated contribution of LAC. Next, conducted...
Epilepsy is a multifaceted neurological disorder characterized by recurrent seizures and associated with molecular immune alterations in key brain regions. The GASH/Sal (Genetic Audiogenic Seizure Hamster, Salamanca), genetic model for audiogenic epilepsy, provides powerful tool to study seizure mechanisms resistance predisposed individuals. This investigates the proteomic responses triggered kindling inferior colliculus, comparing non-responder animals exhibiting reduced severity following...
Erythropoietin (EPO) is not only a hormone that promotes erythropoiesis but also has neuroprotective effect on neurons attributed to its known anti-apoptotic action. Previously, our group demonstrated recombinant-human EPO (rHu-EPO) can protect and recovery motor activity in chemical focal brain hypoxia model (Merelli et al., 2011). We others have reported repetitive seizures mimic hypoxic- like condition by HIF-1α nuclear translocation high neuronal expression P-gp. Here, we report single...
Uncontrolled repetitive generalized tonic-clonic seizures (GTCS) are the main risk factor for sudden unexpected death in epilepsy (SUDEP). GTCS can be observed models such as Pentylenetetrazole kindling (PTZ-K) or pilocarpine-induced Status Epilepticus (SE-P), which share similar alterations cardiac function, with a high of SUDEP. Terminal arrhythmia SUDEP develop result rate hypoxic stress-induced by convulsions excessive sympathetic overstimulation that triggers neurocardiogenic injury,...
P-glycoprotein (P-gp) has been associated with pharmacoresistance and mechanisms regulating the membrane potential. However, at present it is unknown if P-gp overexpression in brain changes depolarization refractory epilepsy. Experiments were designed to evaluate induced by repetitive pentilenetetrazole (PTZ)-induced-seizures. Wistar rats daily treated PTZ during 4 7 days (PTZ4 PTZ7 groups), was used potential vitro electrophysiological procedures using bis-oxonol dye,...
Sudden unexpected death in epilepsy (SUDEP) is the major cause of those patients suffering from refractory (RE), with a 24-fold higher risk relative to normal population. SUDEP increases seizure frequency and/or seizure-duration as RE and Status Epilepticus (SE). P-glycoprotein (P-gp), product multidrug resistant ABCB1-MDR-1 gene, detoxifying pump that extrudes drugs out cells can confer pharmacoresistance expressing cells. Neurons cardiomyocytes normally do not express P-gp, however, it...
It is estimated that 20-25% of epileptic patients fail to achieve good control with antiepileptic drug (AED) treatment; thus, refractory epilepsy (RE) has been described in who have adequate therapeutic levels AEDs without seizures. Multidrug resistance genes reported be highly expressed brain RE. Persistent low plasma and high expression the multidrug product P-glycoprotein (P-gp) previously communicated a case report RE secondary tuberous sclerosis. Here, authors an 8-year-old boy...